Parker Institute for Cancer Immunotherapy
12
2
4
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
25.0%
3 terminated/withdrawn out of 12 trials
62.5%
-24.1% vs industry average
0%
0 trials in Phase 3/4
120%
6 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme
Role: collaborator
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Role: collaborator
Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma
Role: collaborator
Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma
Role: collaborator
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
Role: collaborator
Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention
Role: lead
DC Vaccine in Colorectal Cancer
Role: collaborator
Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
Role: lead
Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer
Role: lead
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
Role: collaborator
Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Role: lead
Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
Role: lead
All 12 trials loaded